Adaptive Biotechnologies set 2026 guidance expecting 20–30% growth in its minimal residual disease (MRD) business, driven by broader ClonoSeq adoption across hematologic malignancies, higher test volume, deeper community penetration and EMR integrations. The company reported strong Q4 and full‑year 2025 revenue gains, forecasted a rise in average selling price for ClonoSeq, and highlighted expanding registrational use of MRD as a clinical endpoint. Adaptive is positioning MRD testing as a durable revenue engine that supports both clinical diagnostics and biopharma trial services; payor negotiations and clinical guideline endorsements will determine how rapidly the MRD market scales.